Fast Five Quiz: Idiopathic Pulmonary Fibrosis Treatment

Guy W. Soo Hoo, MD, MPH; Zab Mosenifar, MD


December 13, 2022

Antifibrotic agents, namely nintedanib and pirfenidone, are the only medications approved by the US Food and Drug Administration for the treatment of IPF. Although these drugs are not curative, they have been shown to slow the fibrotic changes associated with IPF. In real-life studies, both agents have been shown to be effective in reducing decline of forced vital capacity and diffusing lung capacity at 24 months.

TNF-alpha inhibitors were previously investigated as a method for decreasing the progression of fibrosis in patients with IPF. However, trials examining etanercept failed to show benefit, and it is not recommended for use in patients with IPF.

Anticoagulants and antihypertensives are usually not used in treatment of IPF.

Learn more about antifibrotic agents in the treatment of IPF.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.